https://www.selleckchem.com/pr....oducts/selonsertib-g
In model 2 after adjusting for receipt of treatment, there was no difference in OS for B-US when compared to W-US. After adjusting for all variables (model 3), all race/ethnicity profiles had better OS when compared to W-US; B-NUS patients had similar OS to W-US. Foreign-born patients with NSCLC have decreased risk of mortality when compared to native-born patients in California after accounting for treatments received and socioeconomic differences. Foreign-born patients with NSCLC have decreased risk of mortality when compa
Like
Comment
Share
